News
The FDA has extended the review period for elinzanetant for the treatment of moderate to severe vasomotor symptoms due to menopause.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback